Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022028 Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement on 2022 annual guarantee plan
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important note: in 2022, Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as “the company”, “the company” or ” Shanghai Pharmaceuticals Holding Co.Ltd(601607) “) and its subsidiaries are expected to provide external guarantees equivalent to no more than RMB 29052245 million, accounting for about 58.86% of the company’s audited net assets attributable to shareholders of listed companies on December 31, 2021.
As of the disclosure date of the announcement, the actual external guarantee balance of the company and its holding subsidiaries was RMB 9368411700, accounting for about 18.98% of the company’s audited net assets attributable to shareholders of listed companies on December 31, 2021. The guarantees provided in the external guarantee plan in 2022 are provided according to the share ratio, with contingent counter guarantee guarantee. As of the disclosure date of the announcement, the company and its holding subsidiaries had no overdue guarantee. 1、 Overview of guarantee
